CD79b-directed antibody–drug conjugate that delivers monomethyl auristatin E (MMAE), a microtubule inhibitor, to B cells to induce apoptosis.
CD79b-directed antibody–drug conjugate that binds CD79b on B cells, is internalized, and releases monomethyl auristatin E (MMAE) via a cleavable linker; MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD79b-positive malignant B cells.
YES
DIRECT
The ADC binds CD79b on B cells, is internalized, and releases MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD79b-positive cells.
CD79b-directed antibody–drug conjugate that delivers monomethyl auristatin E (MMAE), a microtubule inhibitor, to B cells to induce apoptosis.
CD79b-directed antibody–drug conjugate that binds CD79b on B cells, is internalized, and releases monomethyl auristatin E (MMAE) via a cleavable linker; MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD79b-positive malignant B cells.
NO
INDIRECT
The ADC targets CD79b on B cells, is internalized, and releases MMAE; MMAE binds beta-tubulin (vinca site) to disrupt microtubules, causing G2/M arrest and apoptosis in CD79b-positive cells. Tubulin expression alone does not trigger killing.
Chimeric anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC, and can also induce apoptosis of the target cells.
A B7-H3–targeted antibody–drug conjugate consisting of a human IgG1 monoclonal antibody to B7-H3 (CD276) linked to a deruxtecan payload (exatecan-derived topoisomerase I inhibitor); binding to B7-H3 leads to internalization and release of the payload, causing topo-I–mediated DNA damage and apoptosis with potential bystander effect.
B7-H3–targeted IgG1 antibody–drug conjugate; the antibody binds B7-H3 (CD276) on tumor cells, is internalized, and a cleavable linker releases a deruxtecan (exatecan-derived) topoisomerase I inhibitor payload that causes DNA damage and apoptosis, with potential bystander cytotoxicity.
YES
DIRECT
ADC binds B7-H3 on target cells, is internalized, and releases a deruxtecan topoisomerase I inhibitor that induces DNA damage leading to apoptosis (with possible bystander killing).
Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
YES
DIRECT
rATG contains antibodies that bind HLA-DR on the cell surface and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytosis, causing apoptosis/lysis of the targeted cells.